CD36 and hepatocellular carcinoma: Then, we explored the efficacy of single agents (CD36 inhibitor or anti-PD-1 therapy) and combination treatment strategies (CD36 inhibition and anti-PD-1 therapy) in a C57/BJ6 CTNNB1N90;Trp53KO HCC model and our established anti-PD1 resistant HCC.